Estradiol

Estradiol carries two reputations, and both get in the way of understanding it. The first is that it is simply "the female hormone," a women's concern with no relevance to men. The second, popular in certain corners of men's health, is that estrogen is an enemy of masculinity to be suppressed as low as possible. Each is wrong in an instructive way, and unlearning them is most of what it takes to read this number well.

Estradiol is the body's principal estrogen, and it is essential to both sexes. In women it is the conductor of the reproductive cycle and far more, helping maintain bone, blood vessels, brain, and skin. Its decline at menopause is one of the most consequential hormonal events in human life. In men it is present at much lower levels, made from their own testosterone, and it turns out to be necessary for their bones, their libido, and a healthy amount of body fat.

That dual nature makes estradiol unusually context-dependent to interpret. In women, a single value means almost nothing without knowing the day of the cycle or whether menopause has passed. In men, the question is balance: enough, but not too much. Read with that context, it is one of the more revealing hormones on a panel. Read without it, it is a number that invites exactly the two mistakes above.

Estradiol is the most potent estrogen, acting through receptors found in bone, blood vessels, brain, breast, the reproductive tract, and beyond. In premenopausal women it is produced mainly by the ovarian follicles and rises and falls across the cycle, low in the early days, peaking just before ovulation, then producing a second smaller rise. After menopause, ovarian production essentially stops, and the little estradiol that remains comes from elsewhere.

That "elsewhere" is the key to estradiol in men and in older women: an enzyme called aromatase, concentrated in fat tissue, converts testosterone and related androgens into estradiol. This is why body fat raises estrogen, and why an overweight man can have a low testosterone and a relatively high estradiol at the same time, the one being converted into the other. It also means a man's estradiol is, quite literally, made from his own testosterone.

The roles reach well beyond reproduction. Estradiol is the dominant hormone regulating the skeleton in both sexes: it restrains the cells that break bone down, and its loss is the central driver of postmenopausal osteoporosis. Strikingly, the same is true in men, whose bone density tracks more closely with estradiol than with testosterone ^[1]. It also supports blood vessel function and influences the lipid profile, which is part of why cardiovascular risk in women climbs after menopause.

The clearest evidence that estradiol matters in men comes from an experiment that separated its effects from testosterone's. When healthy men had their hormones suppressed and then replaced with testosterone, with or without a drug that blocked its conversion to estradiol, testosterone turned out to govern muscle and strength, while estradiol governed fat accumulation and contributed substantially to libido ^[2]. Combined with the bone evidence, this makes estradiol an essential male hormone, and the common practice of suppressing it to maximize testosterone a genuine mistake. High estradiol in men is also undesirable, but it usually reflects excess body fat driving aromatization, and the remedy is to lose the fat, not to attack the hormone.

For women, the dominant story is menopause. As estradiol falls, the most effective treatment for the resulting hot flashes, sleep disruption, and genitourinary symptoms, and the prevention of bone loss, is hormone therapy, with a benefit-risk balance that is favorable for most healthy symptomatic women who are under 60 or within 10 years of menopause ^[3]. The risks that frightened a generation away from hormone therapy, seen most clearly in the large Women's Health Initiative trial, fell disproportionately on older women who started treatment long after menopause.

That pattern is not a coincidence; it is the timing hypothesis. In a randomized trial, estradiol slowed the progression of early atherosclerosis when started within six years of menopause but did nothing when started ten or more years out ^[4]. Estrogen's effect on the blood vessels depends on when it is given, which is why hormone therapy is a different proposition at 52 than at 65. The timing principle applies most clearly to the heart and blood vessels; the modest increase in breast cancer with combined estrogen-progestogen therapy is a separate, duration-related risk that remains part of the individual calculation. None of this is a recommendation for or against it; it is the context that turns hormone therapy from a slogan into an individualized decision.